Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | 阶段
第二阶段
|
Date Added 2022-11-08 |
地点
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States 比利时 巴西 法国 格鲁吉亚 意大利 Russian Federation 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
标签
MSS/ MMRp
|
| NCT ID NCT04895709 |
Title一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究 | 阶段
Phase 1, Phase 2
|
Date Added 2021-05-20 |
地点
California, United States
Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 德国 以色列 意大利 日本 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BMS-936558-01, BMS-986340 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03400332 |
TitleBMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究 | 阶段
第二阶段
|
Date Added 2018-01-17 |
地点
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States 澳大利亚 比利时 加拿大 法国 德国 意大利 波兰 西班牙 瑞典 瑞士 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BMS-986253, Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03289962 |
TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | 阶段
第 1 阶段
|
Date Added 2017-09-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States 比利时 加拿大 德国 荷兰 西班牙 瑞典 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Autogene cevumeran, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT05684211 |
Title阿美单抗与抗 PD-1 单克隆抗体和 FOLFIRI 联合用于 RAS 野生型晚期结直肠癌患者的研究 | 阶段
第二阶段
|
Date Added 2023-01-13 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
阿米妥单抗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05167409 |
TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-22 |
地点
Arizona, United States
Colorado, United States New Jersey, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-05-19 |
地点
California, United States
中国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT02988960 |
TitleA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2016-12-12 |
地点
California, United States
Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States 澳大利亚 加拿大 法国 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ABBV-181, ABBV-927, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-02 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | 阶段
第 1 阶段
|
Date Added 2015-11-17 |
地点 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
标签
MSS/ MMRp
|
